Semaglutide's Potential Role in Treating Disordered Eating in Type 2 Diabetes
Background
Disordered eating behaviors are common among individuals with Type 2 Diabetes and overweight, complicating disease management and impacting quality of life. Current treatments often focus on glycemic control or weight loss, but specific interventions for co-occurring eating disorders in this population are limited. This prospective study aims to evaluate the effect of semaglutide, a GLP-1 receptor agonist, on disordered eating behavior in patients with Type 2 Diabetes.
Results
While this study is currently planned and has no results yet, it aims to investigate several key outcomes. The primary objective is to determine if semaglutide treatment can significantly reduce disordered eating behaviors in patients with Type 2 Diabetes and overweight, as assessed by a validated questionnaire. Researchers will also measure changes in serum concentrations of incretin hormones, specifically GLP-1 and GIP, and evaluate glucose variability over 14 days using CGM devices. > The central aim is to quantify the influence of semaglutide on disordered eating behaviors in patients with Type 2 Diabetes and overweight, comparing treated groups to controls over a 12-week period. They will analyze whether semaglutide treatment results in improved glucose variability and altered incretin hormone levels, correlating these changes with any observed improvements in eating disorder symptoms.
Why It Matters
If successful, this study could highlight a novel therapeutic benefit of semaglutide beyond its established roles in glycemic control and weight management. Identifying an effective pharmacological intervention for disordered eating in Type 2 Diabetes patients could significantly improve patient outcomes and quality of life. Positive findings could pave the way for semaglutide to be considered a dual-purpose treatment, addressing both metabolic dysfunction and psychological eating patterns. Future steps would likely involve larger, multi-center trials to confirm efficacy and safety in diverse populations.